Open Access Highly Accessed Research article

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

Gabriele D Maurer1, Daniel P Brucker1, Oliver Bähr1, Patrick N Harter2, Elke Hattingen3, Stefan Walenta4, Wolfgang Mueller-Klieser4, Joachim P Steinbach1 and Johannes Rieger1*

Author Affiliations

1 Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Schleusenweg 2-16, 60528 Frankfurt, Germany

2 Institute of Neurology (Edinger Institute), Goethe University Hospital, Heinrich-Hoffmann-Str. 7, 60528 Frankfurt, Germany

3 Institute of Neuroradiology, Goethe University Hospital, Schleusenweg 2-16, 60528 Frankfurt, Germany

4 Institute of Physiology and Pathophysiology, Gutenberg University Medical Center, Duesbergweg 6, 55099 Mainz, Germany

For all author emails, please log on.

BMC Cancer 2011, 11:315  doi:10.1186/1471-2407-11-315

Published: 26 July 2011

Additional files

Additional file 1:

Figure S1. The presence of 3-hydroxybutyrate does not modify glucose consumption or lactate generation of the glioma cell lines. U87MG, U251MG, LNT-229, T98G and A172 cells were cultured in medium containing 5 mM glucose and 5 mM 3-hydroxybutyrate (3OHB). Glucose and lactate concentrations of cell culture supernatants were analyzed on days 1, 2, 3, 4, 5 and 6.

Format: PDF Size: 438KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data

Additional file 2:

Figure S2. Expression of HIF-1α target genes is not modulated by 3-hydroxybutyrate. LNT-229 cells were either untreated or treated with 3-hydroxybutyrate for 24 h at normoxia or hypoxia, and the expression of the HIF-1α target genes GLUT1, VEGF or MCT4 was analyzed by real-time quantitative PCR (fold change in gene expression normalized to the internal control 18S rRNA; mean and standard deviation).

Format: PDF Size: 330KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data